What is cannabichromene (CBC)?

Author: Dipl.-Chem. Mohammad Reza Talebnasab
Editorially reviewed: 13 October 2026

CBC stands for cannabichromene, known as Cannabichromen in German. It is one of the plant cannabinoids found in cannabis. CBC is neither CBD nor CBN: these similar-sounding names refer to different chemical compounds. Its formation in the plant and its activity at particular receptors and ion channels are of particular scientific interest. However, what these laboratory findings mean for humans remains insufficiently understood.

In brief: CBC has been investigated in biochemical studies, cell and animal experiments, and initial human studies using CBC-containing combination preparations. These different types of research must not be equated. The results described here do not establish an independent therapeutic benefit of CBC.

How does CBC form in the cannabis plant?

The plant's biosynthetic pathway begins with cannabigerolic acid, or CBGA. The enzyme cannabichromenic acid synthase can convert CBGA into cannabichromenic acid (CBCA). This reaction was investigated using an enzyme obtained from cannabis. CBCA is the acid precursor of CBC, not simply another name for the same substance. Morimoto et al., 1998: investigation of CBCA synthase.

Decarboxylation converts CBCA into the neutral cannabinoid CBC. Carbon dioxide is released during this process; heat can promote it. In simplified form, the sequence is CBGA → CBCA → CBC. Similar conversions affect other cannabinoid acids, such as CBDA, the precursor of CBD. When interpreting plant analyses, it is therefore important to establish whether acid forms and neutral cannabinoids were measured separately. Analytical investigation of cannabinoids before and after heat treatment, 2022.

CBC, CBD, CBG and CBN: what is the difference?

Cannabidiol (CBD) forms through the CBDA branch of biosynthesis. Cannabigerol (CBG) forms through CBGA decarboxylation. More precisely, CBGA is a shared starting material for several pathways; neutral CBG should not simply be called the ‘mother of all cannabinoids’.

Cannabinol (CBN) can instead form through the breakdown and oxidation of THC. A long-term investigation of stored cannabis samples shows that light and temperature affect changes in cannabinoid composition. CBC and CBN must therefore also be distinguished by how they form. Zamengo et al., 2019: storage and cannabinoid changes.

Belonging to the same substance group does not imply identical effects. A study of CBD, CBG or CBN does not automatically answer a research question about CBC. Likewise, the word ‘CBC’ does not establish the THC content of an entire extract.

CBC's effects: what do researchers investigate in the laboratory?

CBC is investigated at cannabinoid receptors, among other targets. In 2019, Udoh and colleagues observed CB2 receptor activation but no corresponding CB1 response in the cell assay they used. Another study by Zagzoog and colleagues in 2020 found partial activity at both receptors in other cell assays. It would therefore be too sweeping to state that ‘CBC acts exclusively at CB2 and never at CB1’. Different cell models and measured signalling pathways must be considered when interpreting such findings. Udoh et al., 2019; Zagzoog et al., 2020.

Researchers are also interested in TRP ion channels. These membrane proteins allow charged particles to pass through and influence cellular signal processing. In a cell model, CBC activated the TRPA1 channel studied in particular. This is a finding about a biological mechanism, not evidence of pain relief in humans. De Petrocellis et al., 2011: TRP channels and cannabinoids. Our page on the endocannabinoid system explains the broader principles.

Inflammation, skin and nerve cells: preclinical research areas

Inflammation models: CBC altered certain inflammatory parameters in activated mouse immune cells. More favourable tissue and inflammation findings were also observed in an experimentally induced intestinal inflammation model in mice. The study did not investigate treatment in people with inflammatory bowel disease. Romano et al., 2013.

Skin research: in cultured human sebaceous-gland cells, CBC affected lipid production and the inflammatory responses studied. Cell death was also observed at high test concentrations. Human cells in a laboratory are not a clinical study: neither effective acne treatment nor the skin tolerability of a finished product is established by these findings. Oláh et al., 2016.

Neural progenitor cells: another study investigated the survival and differentiation of such cells from mice. CBC affected particular cell characteristics. This does not establish that CBC produces new functional nerve cells in the human brain, improves memory or protects against dementia. Shinjyo and Di Marzo, 2013.

What human studies of CBC are available?

Absorption in the body: a pharmacokinetic pilot study assessed data from 43 healthy adults. Participants were assigned for seven days to a preparation containing CBD, THC and CBC in four different dose groups, or to placebo. Researchers measured CBC in the blood and described its concentration over time. The study investigated neither isolated CBC nor treatment of a disease. No general dosage recommendation or superiority of arbitrary CBC products can be inferred. Peters et al., 2021/2022.

Sleep: a randomised, blinded comparative study involving 1,793 adults investigated six preparations over four weeks. One preparation contained CBD, CBN and CBC. This combination showed no statistically established advantage over CBD alone for the sleep measure studied. There was no CBC-only group and no placebo group. Improvements within individual groups therefore do not establish a specific CBC effect. Saleska et al., 2023/2024.

Chronic pain: a comparative study published in 2026 also investigated a CBC-containing combination, together with THCA, CBDA and CBG. Of 276 people recruited, 164 were included in the final per-protocol analysis. Multiple ingredients, self-reports, the absence of placebo and participant losses limit the strength of the findings. In particular, reported changes must not be attributed to CBC alone. Kruger et al., 2026.

The precise summary is therefore not ‘There are no human studies’. There are initial data on CBC in combination preparations, but they do not reliably establish the independent benefit of CBC for a particular condition.

Is CBC intoxicating – and what is known about safety?

CBC is generally classified as a non-intoxicating cannabinoid. This is not equivalent to ‘without biological effects’ or ‘free of adverse effects’. A substance without a typical THC high can still influence biological processes. Clinical data are insufficient for a comprehensive assessment of rare risks, long-term use or particularly susceptible populations.

An important research signal comes from a 2025 study using a human liver chip, a laboratory model with human liver cells. CBC-related cell damage was observed under the conditions studied. This is not documented liver damage in people using CBC and does not allow a safe or dangerous intake amount to be directly inferred. It does, however, illustrate why ‘plant-based’ must not be equated with ‘proven safe’. Larson et al., 2025: liver-chip investigation.

CBC and medicines: what interactions are known?

How CBC interacts with medicines has not been sufficiently investigated in humans. A study using human liver enzymes and supplementary mouse experiments describes the formation of various CBC metabolites. However, an enzyme being able to metabolise CBC does not automatically mean that CBC inhibits it to a clinically relevant extent or increases another medicine's blood concentration. Roy et al., 2024: CBC metabolism.

Known CBD or THC interactions must not be transferred unchanged to CBC. Likewise, claiming ‘no interactions’ without sufficient research would not be reliable. If you take medicines regularly, seek advice from a doctor or pharmacist; do not stop or change the dose of prescribed medicines yourself. We explain the general mechanisms in Cannabinoids and medicines: interactions.

What does an analytical report say about CBC?

An analytical report initially answers an analytical question: which substances were measured in a particular sample, using which method and in what quantities? Check the sample or batch identification, units and detection and quantification limits. CBC must not be confused with its acid precursor CBCA.

A measured CBC content establishes neither a health benefit nor the safety or absence of THC in the entire product. These require separate questions to be answered. Our laboratory reports page links to the product analyses made available there; it is not clinical evidence of CBC's efficacy.

Conclusion: a research subject, not an established efficacy promise

Cannabichromene is a distinct cannabinoid compound with an identifiable plant biosynthetic pathway and interesting laboratory findings. A credible assessment, however, depends on appropriate evidence, not the greatest possible number of potential ‘effects’. The original studies linked here differ considerably in their methods and what they can establish. Results from cell cultures, mice and cannabinoid combination preparations provide avenues for research, but no established treatment recommendation for CBC alone.

Note: this article provides general scientific information. It does not replace individual medical advice, diagnosis or treatment and contains no dosage or use recommendations. The studies mentioned did not investigate Parmorcan® products. Sources are linked directly alongside the respective statements.